Major Cancer Genome Breakthrough Could Transform Treatment
Groundbreaking research mapping the complete genetic landscape of tumours has revealed that significantly more patients with breast and ovarian cancer could benefit from targeted precision therapies than previously thought. Scientists from the Manchester Cancer Research Centre and the Institute of Cancer Research have achieved a world-first by decoding the full spectrum of mutations driving cancer growth, potentially ushering in a new era of personalised medicine.
Unprecedented Scale of Genetic Analysis
The landmark study, published in Nature Genetics, involved analysing an enormous dataset from 10,983 cancer patients participating in the 100,000 Genomes Project. Over six years, researchers examined tumours across 16 different cancer types using whole-genome sequencing technology. This comprehensive approach allowed them to catalogue 370 million mutations and identify 134 distinct mutational "signatures" - patterns of DNA damage that act like fingerprints revealing what caused the cancer.
Remarkably, 26 of these signatures were completely new discoveries not previously included in the widely-used Catalogue of Somatic Mutations in Cancer (Cosmic) database. This represents a substantial expansion of scientific understanding about the genetic drivers of cancer development.
Targeted Therapy Implications
The research identified homologous recombination deficiency (HRD) - a specific weakness in DNA repair mechanisms - in 16% of breast cancer tumours and 14% of ovarian cancer tumours. This deficiency makes cancers particularly vulnerable to targeted drugs like PARP inhibitors and platinum-based chemotherapy.
Based on UK cancer incidence figures, researchers estimate this discovery means more than 7,700 breast cancer patients and 1,000 ovarian cancer patients annually could potentially benefit from HRD-targeted therapies. This represents a substantial increase over the numbers currently identified through standard genetic testing for BRCA1/BRCA2 gene mutations alone.
Professor David Wedge, professor of cancer genomics and data science at the University of Manchester, explained: "Every cancer develops because DNA is damaged over time. Different causes such as ultraviolet light, tobacco smoke or inherited gene faults leave different patterns in the genome. By reading these patterns we can now understand, in a larger proportion of cancers, what caused the cancer, when key mutations occurred, and which treatments are most likely to work."
Broader Cancer Insights
The study also provides crucial insights into the worrying rise of bowel cancer among younger adults. Researchers discovered that toxins produced by particular strains of E. coli bacteria in the gut leave distinctive mutational signatures that occur more frequently in younger patients than older ones.
This finding supports emerging theories about environmental factors contributing to the 52% increase in bowel cancer incidence rates among adults aged 25 to 49 since the early 1990s. Cancer Research UK data indicates one in 20 bowel cancers is now diagnosed in people under 50.
Clinical Implications and Expert Reactions
While researchers emphasise that clinical trials are needed to confirm patients with HRD signatures respond to PARP inhibitors, the potential implications are substantial. Professor Richard Houlston, head of cancer genomics at the Institute of Cancer Research in London, stated: "This study provides one of the clearest demonstrations yet that reading the full genetic history of a tumour can unlock clues to better patient care. The future of cancer treatment lies not just in finding mutations, but in understanding the story they tell."
Simon Vincent, chief scientific officer at Breast Cancer Now, commented: "This research demonstrates the potential of whole-genome sequencing in helping to ensure more people diagnosed with breast cancer receive the most effective treatment for them. These findings suggest that more people with breast cancer might benefit from targeted drugs like PARP inhibitors than current genetic testing identifies."
Catherine Hart, chief executive of Target Ovarian Cancer, added: "This could be a huge breakthrough in understanding which gene differences can cause ovarian cancer and how to treat it. These findings have the power to transform treatment and, ultimately, improve thousands of women's chances of survival."
The research represents a significant step toward more precise, effective, and personalised cancer treatment options for the 55,000 women and 400 men diagnosed with breast cancer annually in the UK, along with thousands of ovarian cancer patients.
